Lantheus Q3 revenues grow, but so does net loss

2020 02 20 18 12 3118 Money Bills 400

Lantheus Holdings reported revenue growth for the company's third quarter of fiscal 2021, but the company's net loss more than doubled.

For the period (end-September 30), the company said its revenue for the quarter was $102.1 million, an increase of 15.3% from the previous year when it posted sales of $88.5 million. The firm's net loss under generally accepted accounting principles (GAAP) was $13.4 million for the quarter, compared with a net loss of $6.4 million in the previous year.

Lantheus said the revenue growth can be attributed to adoption of its Pylarify prostate-specific member antigen (PSMA) PET imaging agent, as well as continued growth of its Definity and TechneLite products. Lantheus will also continue its ongoing Arrow phase II study of 1095, a PSMA-targeted therapeutic.

Page 1 of 592
Next Page